NCT05940064View on ClinicalTrials.gov

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 20, 2025

Study Completion Date

December 31, 2025

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Zanubrutinib, Polatuzumab Vedotin, Rituximab

Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital，Fudan University, Shanghai

All Listed Sponsors

lead

Peng Liu

OTHER